TL;DR: The Centers for Medicare & Medicaid Services modified NCD 21, its coverage policy for intravenous histamine therapy, effective January 9, 2026. The policy confirms a full non-coverage position — histamine therapy is not reimbursable under Medicare for any condition, by any route of administration.
This update to NCD 21 in the CMS Medicare system reinforces what the agency has maintained for decades: histamine therapy has no scientifically valid therapeutic application, and Medicare will not pay for it. No specific CPT or HCPCS codes are listed in this policy. If your billing team has ever submitted a claim for histamine therapy — or fields requests to do so — this is your definitive answer.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Intravenous Histamine Therapy — NCD 21 |
| Policy Code | NCD 21 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | Low — but high claim denial risk if billed |
| Specialties Affected | Internal medicine, neurology, integrative/alternative medicine, gastroenterology |
| Key Action | Reject any order for histamine therapy before it hits your charge capture — this service is not covered under Medicare for any indication |
CMS Histamine Therapy Coverage Criteria and Medical Necessity Requirements 2026
CMS histamine therapy coverage policy under NCD 21 is unambiguous. Histamine has exactly one accepted clinical use category under Medicare: diagnostic testing. That's it.
The policy identifies four specific diagnostic applications where histamine is scientifically valid:
| # | Covered Indication |
|---|---|
| 1 | Assessing the stomach's ability to secrete acid |
| 2 | Testing the integrity of peripheral sensory nerves (including evaluation in leprosy) |
| 3 | Evaluating circulatory competency in limb extremities |
| 4 | Detecting the presence of a pheochromocytoma |
These are diagnostic uses — not therapeutic ones. If a provider orders histamine to assess gastric acid secretion or peripheral nerve function, that's the line CMS draws. Therapeutic use of histamine, including intravenous administration, gets no coverage under Medicare regardless of the clinical rationale.
The medical necessity standard here is clear. CMS states directly that "there is no scientifically valid clinical evidence that histamine therapy is effective for any condition regardless of the method of administration." That language covers IV histamine, subcutaneous histamine, intradermal histamine — all of it. There is no pathway to medical necessity for therapeutic histamine under Medicare, and there is no prior authorization process that can unlock coverage. Prior authorization doesn't create coverage where none exists.
For reimbursement purposes, any claim for histamine therapy as a treatment — not a diagnostic tool — will be denied. Full stop.
CMS Histamine Therapy Exclusions and Non-Covered Indications
The real issue with NCD 21 isn't the policy itself — it's how histamine therapy gets billed in practice. Some providers, particularly in integrative medicine, functional medicine, or allergy management settings, may order histamine-based treatments and expect their billing team to find a path to reimbursement. There isn't one under Medicare.
CMS is explicit: histamine therapy "is not accepted or widely used by the medical profession" for any therapeutic purpose. The agency goes further and states it "cannot be considered reasonable and necessary." Those two phrases together are the death knell for any claim.
The method of administration doesn't matter. IV, injection, topical — none of it changes the coverage status. If the service is histamine therapy as a treatment, it is excluded from Medicare payment under NCD 21.
This creates a specific downstream risk for your billing team. If a provider documents histamine therapy in a procedure note and your team submits a claim without recognizing the non-covered status, that's a claim denial waiting to happen — and potentially a compliance issue if the patient wasn't properly informed about non-coverage.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Diagnostic assessment of gastric acid secretion | Covered (diagnostic use only) | No specific codes listed in NCD 21 | Must be billed as diagnostic, not therapeutic |
| Testing integrity of peripheral sensory nerves (e.g., leprosy evaluation) | Covered (diagnostic use only) | No specific codes listed in NCD 21 | Must be billed as diagnostic, not therapeutic |
| Evaluating circulatory competency in limb extremities | Covered (diagnostic use only) | No specific codes listed in NCD 21 | Must be billed as diagnostic, not therapeutic |
| Detection of pheochromocytoma | Covered (diagnostic use only) | No specific codes listed in NCD 21 | Must be billed as diagnostic, not therapeutic |
| Histamine therapy for any therapeutic condition — any route of administration | Not Covered | No specific codes listed in NCD 21 | No medical necessity pathway exists under Medicare |
| Intravenous histamine therapy specifically | Not Covered | No specific codes listed in NCD 21 | CMS cites no valid clinical evidence for therapeutic use |
CMS Histamine Therapy Billing Guidelines and Action Items 2026
NCD 21 took effect January 9, 2026. Here's what your billing team should do now.
| # | Action Item |
|---|---|
| 1 | Audit your charge master and charge capture for any histamine-related service lines. If histamine therapy appears anywhere as a billable item for Medicare patients, flag it immediately. This is not a covered service. Remove it from any fee schedule entry tied to Medicare billing. |
| 2 | Brief your clinical staff — especially in integrative medicine, allergy, and neurology — before they submit orders. The prescribing provider may not know the CMS coverage policy under NCD 21. A denied claim is a billing problem. An uncollected ABN is a compliance problem. Both are preventable. |
| 3 | Issue an Advance Beneficiary Notice of Noncoverage (ABN) for any patient requesting histamine therapy. Because NCD 21 establishes a clear non-coverage position, Medicare patients must be notified in writing before receiving this service if the provider still intends to perform it. Without an ABN, you cannot bill the patient either. |
| 4 | Do not confuse diagnostic histamine testing with therapeutic histamine therapy in your documentation. The four diagnostic indications listed in NCD 21 may be reimbursable — but only if they're properly documented and coded as diagnostic procedures. Check with your Medicare Administrative Contractor for local guidance on which codes apply to diagnostic histamine testing in your region, since NCD 21 does not specify codes. |
| 5 | Check for any local coverage determinations from your MAC that may address histamine-related diagnostic codes. NCD 21 governs therapeutic histamine at the national level. Diagnostic histamine use may have LCD-level guidance depending on your region. If your team bills gastric secretion tests or pheochromocytoma workups that involve histamine, contact your MAC or talk to your compliance officer to confirm the right coding approach. |
| 6 | Do not attempt to route histamine therapy claims through alternative payers to offset Medicare non-coverage. Some billing teams assume that if a service is non-covered by Medicare, secondary or supplemental payers will pick it up. Most supplemental plans follow Medicare's coverage determinations. Don't build a billing workaround on a non-covered foundation. |
If you're in an integrative medicine or functional medicine setting that routinely offers histamine-based treatments, talk to your compliance officer before the January 9, 2026 effective date — or as soon as possible if that date has already passed. The financial exposure from billing non-covered services without ABNs is real.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Histamine Therapy Under NCD 21
Covered CPT Codes
NCD 21 does not list specific CPT or HCPCS codes for the covered diagnostic uses of histamine. The policy identifies covered diagnostic indications in clinical terms only.
For diagnostic histamine billing — gastric acid secretion testing, peripheral nerve integrity testing, circulatory evaluation, or pheochromocytoma detection — you'll need to identify the appropriate CPT or HCPCS codes through your MAC or a qualified billing consultant. Do not assume a code is covered simply because the underlying diagnostic use is recognized in NCD 21.
Not Covered / Experimental Codes
NCD 21 does not list specific CPT or HCPCS codes for excluded therapeutic histamine services. The policy excludes therapeutic histamine therapy by clinical description, not by code.
This matters for your team. The absence of specific excluded codes doesn't create a billing opportunity. If a service is histamine therapy administered therapeutically, it's not covered — regardless of which code you attach to it.
Key ICD-10-CM Diagnosis Codes
NCD 21 does not list specific ICD-10-CM diagnosis codes. No diagnosis codes are provided in this policy.
The bottom line on NCD 21: there are no codes to track, no prior auth requirements to manage, and no criteria to meet for the therapeutic side. The policy exists to shut the door on histamine therapy billing — and it does exactly that.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.